Beijing, PTI. Chinese company Sinovac Biotech has claimed that the vaccine Coronavac (CoronaVac), being developed by it to fight against Corona, has given positive results in clinical trials in the first and second stages. The company says that this vaccine is capable of increasing immunity. According to the report of the news agency PTI, a total of 743 volunteers aged 18 to 59 had enrolled for the vaccine trials.
The Beijing-based company said in its statement that 143 of them had joined the first phase and 600 people in the second phase. Those involved in the test were given two injections, after which they did not show any side effects of the vaccine for 14 days. The company hopes to soon report the Phase II and Phase III clinical trials to the China National Medical Products Administration, NMPA. Synovac President and CEO Weidong Yin said that it is capable of increasing immunity.
Weidong said that the completion of the clinical trials of phase one and two is the milestone that we have achieved in the war against Corona. Meanwhile, the British pharmaceutical company ‘AstraZeneca Plc’ has reported that it has signed an agreement with the European Government to supply its potential vaccine against Corona. The agreement has been signed to supply 400 million doses of vaccine. Let us tell you that the University of Oxford is developing this vaccine. The company says that it is also negotiating with Japan, Russia, Brazil and China for an agreement.
We have taken all measures to ensure that the information provided in this article and on our social media platform is credible, verified and sourced from other Big media Houses. For any feedback or complaint, reach out to us at businessleaguein@gmail.com
